Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aplaviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aplaviroc SCHEMBL5578734 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL5346716 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL6190417 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL4821965 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL5578741 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL6186135 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6186236 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL15531476 | 0.99 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5343787 | 0.99 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL4577106 | 0.99 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270429-A1 | Function Inhibitor of Effector Cell | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1623721-A1 | EFFECTOR CELL FUNCTION INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270429-A1 | Function Inhibitor of Effector Cell | CCR5, CXCR3, CCR1 | CCR5 1/4885CYP2C9 3525/4885CXCR4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.